Patents by Inventor Eyal Shteyer
Eyal Shteyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10500226Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than ?25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10?8 cm2/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.Type: GrantFiled: December 30, 2013Date of Patent: December 10, 2019Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion UniversityInventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'Acov
-
Patent number: 10328098Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.Type: GrantFiled: July 10, 2016Date of Patent: June 25, 2019Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development AuthorityInventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Ya'acov, Smadar Cohen, Tsiona Elkayam
-
Patent number: 9993497Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.Type: GrantFiled: December 30, 2013Date of Patent: June 12, 2018Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion UniversityInventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'acov
-
Publication number: 20180099006Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.Type: ApplicationFiled: December 11, 2017Publication date: April 12, 2018Applicants: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion UniversityInventors: Smadar COHEN, Yaron ILAN, Eyal SHTEYER, Ami BEN-YA'ACOV
-
Publication number: 20160317570Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.Type: ApplicationFiled: July 10, 2016Publication date: November 3, 2016Applicants: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development AuthorityInventors: Yaron ILAN, Gadi LALAZAR, Eyal SHTEYER, Ami BEN-YA'ACOV, Smadar COHEN, Tsiona ELKAYAM
-
Patent number: 9387222Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.Type: GrantFiled: November 27, 2008Date of Patent: July 12, 2016Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development AuthorityInventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam
-
Publication number: 20150352144Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.Type: ApplicationFiled: December 30, 2013Publication date: December 10, 2015Inventors: Smadar COHEN, Yaron ILAN, Eyal SHTEYER, Ami BEN-YA'ACOV
-
Publication number: 20150335675Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than ?25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10?8 cm2/millisecond, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease, liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.Type: ApplicationFiled: December 30, 2013Publication date: November 26, 2015Inventors: Smadar COHEN, Yaron ILAN, Eyal SHTEYER, Ami BEN-YA'ACOV
-
Publication number: 20100247652Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.Type: ApplicationFiled: November 27, 2008Publication date: September 30, 2010Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITYInventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam